Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n 5 416), dasatinib (n 5 418) or nilotinib (n 5 408) in the US and 6
| I N TR ODU C TI ON
Over the past 15 years the availability of tyrosine kinase inhibitors (TKIs) has transformed the natural history of chronic phase-chronic myeloid leukemia (CP-CML) from a terminal disease to treatable chronic illness. 1, 2 As a result, survival rates in patients with newly-diagnosed CP-CML approximate those in age-adjusted general populations. [3] [4] [5] [6] The European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN) recommend imatinib (Gleevec®/Glivec ® , Novartis), dasatinib (Sprycel ® , Bristol-Myers Squibb) or nilotinib (Tasigna ® , Novartis) as first-line therapy for CP-CML. 7, 8 All three agents, in research settings, enable CP-CML patients to achieve 1-year complete cytogenetic response (CCyR) rates of 69-80% and 5-year survival rates of 89-96%. [9] [10] [11] [12] [13] Given availability of multiple first-line TKIs, patients and physicians have the opportunity to individualise initial treatment approaches by considering disease-, drug-, patient-, and physician-related factors, such as CML risk score, TKI safety profiles, patients' comorbidities, and economic considerations. [14] [15] [16] However, it remains unclear how these factors influence TKI selection in routine clinical practice.
Once TKI therapy is initiated, careful monitoring of cytogenetic response (CyR) and molecular response (MR), using time-based "milestone" testing, is necessary to ensure optimal outcomes. 8, 17 Both the ELN and NCCN recommend, during the first year of TKI therapy, assessment of response every three months, with an emphasis on MR testing. 7, 8 Retrospective studies report improved overall survival among patients who achieve early MR, particularly at three and six months, further supporting the importance of response monitoring during the first year. 18, 19 Small studies conducted in routine clinical practice have reported, however, that patients may not be monitored as frequently as suggested. [20] [21] [22] [23] SIMPLICITY (NCT01244750) is an ongoing observational study of patients with CP-CML receiving first-line treatment with imatinib, dasatinib or nilotinib in the United States (US) and six European countries (Italy, Germany, Spain, France, the Netherlands and Russia). Its primary objective is to understand TKI use and management patterns in routine clinical practice. Preliminary monitoring patterns and predictors of monitoring have been reported previously. 24 , 25 Here we report data in prospective patients with at least 12 months of follow-up (data cut:
March 07 2017), focusing on baseline demographics, choice of firstline TKI and CyR/MR monitoring patterns.
| M E TH ODS
SIMPLICITY includes three prospective cohorts of newly-diagnosed patients with CP-CML, 18 years at time of diagnosis, receiving firstline therapy with imatinib, dasatinib or nilotinib on or after October 01 2010 (Supporting Information Figure S1 ). Study sites include academic and private/community practices in France, Germany, Italy, the Netherlands, Russia, Spain and the US. Non-US sites were grouped and defined as "Europe". Community practices were defined as small, private practices run by one or more independent physicians offering patient care on a local basis. Academic centers were defined as large, Figure S2 ). The distribution of patients across the US and Europe, and between academic and private/community practices, is shown in Supporting Information Figure S3 . 55% of the US sites were private/community practices compared with 41% of the sites in Europe.
Patient demographics are shown in 
| Physicians' selection of first-line TKI
In 53% of patients, the primary reason cited by the treating physician for selecting first-line TKI was (perceived) "effectiveness". Other reasons that were primary drivers for treatment choice in SIMPLICITY patients included familiarity (11.2%), cost efficiency (10.2%), comorbidities (9.2%), and tolerability (6.4%). The median (IQR) number of baseline comorbidities, in patients whose primary reason for physician selection of first-line TKI was comorbidities, was 3.0 (1.0-5.0); 58% of these patients had CV comorbidities.
| CyR and MR monitoring patterns
Among patients followed for at least 12 months, the median (IQR) time from initiation of first-line TKI to the end of follow-up was 52. Figure S4 ). Monitoring for either CyR/MR was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months ( Table 2) of patients, respectively). Similarly, testing was more frequently performed at academic centers than community practices. At 3 months, 40 .1% of patients were tested for CyR/MR at academic centers compared with 31.3% at community practices. By 12 months, 97.3% at academic centers vs. 93.4% in community practices had documentation of CyR/MR testing (P 5 .001).
| CyR monitoring patterns
The proportion of patients with documentation of CyR monitoring increased with longer patient follow-up; at 3 months only 16% of patients had been tested for CyR, but this increased to 40% by 6 months and 55%
by 12 months (P < .001). Of these, 92% (88% "actionable"; 12% "not actionable"), 90% (92% "actionable"; 8% "not actionable") and 89% (93% "actionable"; 7% "not actionable") of patients had CyR results available by 3, 6, and 12 months, respectively (Table 2) .
A greater proportion of patients in Europe had documentation of CyR monitoring compared with the US by 3, 6 and 12 months, respectively (21% vs. 13%, 51% vs. 34% and 66% vs. 49%; P < .001 for each; Table 2 ). A greater proportion of patients had documented CyR monitoring at academic centers compared with community practices by 3, 6, and 12 months, respectively (20% vs. 12%, 50% vs. 28%, and 66% vs. 43%; P < .001 for each; 28% of patients; Table 2 ).
| MR monitoring patterns
Of the patients followed, 32% had documentation of MR testing by 3 months; this increased to 74% by 6 months and 91% by 12 months (P < .0001) ( Table 2 ). A greater proportion of patients in Europe were (12) 18 (22) 3 (3) 34 (8) 28 (14) 6 (3) 43 (7) 32 (13) 11 (3) Bone marrow karyotyping or FISH FISH, n (%)
139 (11) 49 (11) 90 (11) 330 (27) 112 (27) 218 (27) 447 (37) 148 (36) 299 (38) Bone marrow karyotyping, n (%)
103 (8) 69 (16) 34 (4) 286 (23) 173 (41) 113 (14) 441 (37) 227 (55) 214 (28) Done/recorded with no results available 15 (8) 8 (9) 7 (7) 50 (10) 17 (8) 33 (12) 72 (11) 19 (7) 53 (14) Number of cytogenetic (bone marrow karyotyping or FISH) tests performed, n (%) and 43% in community centers (41% US and 50% Europe) ( Table 2 ). come Study (EUTOS) CML registry. 30 Given other observational studies advocate the use of imatinib in older patients, 31 it is perhaps not surprising that the median age for patients on imatinib was slightly higher compared with that for patients on dasatinib or nilotinib (P < 0.001). It should be noted, however, that the IQR for age is large, reflecting the wide age range in our population. Age may have therefore been a factor determining treatment choice, but this was not captured as a reason for choice of first-line TKI in SIMPLICITY.
| CyR and MR monitoring by year of first-line TKI initiation in SIMPLICITY
A higher proportion of patients had baseline comorbidities in SIM-PLICITY (81%) than in EUTOS (55%) and other studies (36%). Given recent findings that baseline comorbidities may have a greater influence on survival than CML in the TKI era, individualisation of treatment choices is key to enhancing long-term tolerability and adherence. 15, 34 We report the primary reason cited by the treating physician for selecting first-line TKI was (perceived) "effectiveness". In clinical practice, however, treatment choice is influenced by numerous factors, including those relating to the characteristics of the study center, patient characteristics, and preferences and expertise of the prescribing physician. Another factor that may influence TKI choice is Sokal or
Hasford score. Calculation of these risk scores normally requires the measurement of numerous parameters, including the spleen size, that are not routinely assessed during normal clinical practice. 35 As such, only about one third of patients in this observational study had available risk scores. While there are some differences between SIMPLIC-ITY patients with and without Sokal/Hasford risk scores, these risk scores were not significant predictors of response monitoring.
Although the imatinib cohort was filled before either of the secondgeneration cohorts, it is important to note that enrollment into SIM-PLICITY began in each country after all three TKIs were approved and thus the prescribing physician had the option to prescribe any of the TKIs. TKI selection in SIMPLICITY is thus driven by physician choice and perceptions of each agent rather than being a reflection of TKI availability.
Early and routine monitoring of CyR and MR in CML patients is crucial to achieve long-term treatment goals. 20 Timely monitoring helps to ensure that milestone "warning" responses are rapidly identified and acted upon. 7, 8, 36 SIMPLICITY has found that patients may not be moni- One of the strengths of observational research is it allows us to understand better how clinical trial experience translates into routine clinical practice and a wider patient population than normally included in RCTs. 46 However, the robustness of observational research methodologies has been questioned, as their nonrandom design may increase selection bias and confounding, and thus the results from such studies need to be interpreted in clinical context. 46, 47 Importantly, while SIM-PLICITY has been able to capture how patients have been managed in the routine clinical practice setting, reasons for declining participation in the study, and reasons behind the investigators' decisions to include patients in the study were not collected and thus there may be selection bias with respect to the patients included in the study. Selection bias is a known limitation of nonrandomized studies and requires careful inference about study findings. 46, 47 A multivariable logistic regression model allowed for evaluation of response monitoring while simultaneously adjusting for distributional differences in patient characteristics. Age, region, practice type, and whether the patient was still on first-line TKI were all significant predictors at specified timepoints, still not fully in accordance with these recommendations, particularly in the US and in community practices, and in older patients and those no longer receiving first-line therapy. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted. The extent to which the early response monitoring practices identified here on long-term outcomes in SIMPLICITY patients still needs to be determined, and will be the focus of future analyses.
